Association of Baseline Low-Density Lipoprotein Cholesterol and Percentage Low-Density Lipoprotein Cholesterol Reduction With Statins, Ezetimibe, and PCSK9 Inhibition

IMPORTANCE: Low-density lipoprotein cholesterol (LDL-C) is an important modifiable risk factor for atherosclerotic cardiovascular disease. It is unclear whether the percentage LDL-C lowering with pharmacotherapies differs on the basis of baseline LDL-C levels. OBJECTIVE: To evaluate the association...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:JAMA Cardiol
Main Authors: Marcusa, Daniel P., Giugliano, Robert P., Park, Jeong-Gun, de Lemos, James A., Cannon, Christopher P., Sabatine, Marc S.
Formato: Artigo
Idioma:Inglês
Publicado: American Medical Association 2020
Assuntos:
Brief Report
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7666429/
https://ncbi.nlm.nih.gov/pubmed/33185670
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamacardio.2020.6184
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares